Therapeutic strategies aimed at restoring type I IFNs through Stimulator of Interferon Genes (STING) signaling are being investigated in human malignancies.56 Intratumoral injection of the STING agonist, ADU-S100/MIW815, has been demonstrated to inhibit the growth of breast tumors in mice.57 A clinical trial investigating MIW815 combined with ipilimumab(NCT02675439) as well as a trial with MIW815 combined with spartalizumab (anti-PD-1; NCT03172936) are currently ongoing in advanced solid tumors. The gene discussed is STING1; the disease is breast neoplasm.